CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Double and Triple Hit Lymphoma, Double Expressor Lymphoma and High-Grade B Cell Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04479267
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:14.388795+00:00
Published At: 2025-09-29T00:00:00+00:00
Record Updated At: 2025-09-29
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Diffuse Large B-Cell Lymphoma", "High Grade B-Cell Lymphoma w/MYC \u0026 BCL2 or BCL6 Rearrangements", "High Grade B-Cell Lymphoma w/MYC, BCL2 \u0026 BCL6 Rearrangements", "Double Expressor Lymphoma", "High-grade B-cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-09-29"
protocolSection.identificationModule.nctId: "NCT04479267"
protocolSection.identificationModule.officialTitle: "A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Double and Triple Hit Lymphoma, Double Expressor Lymphoma and High-Grade B Cell Lymphoma"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.